Collaboration between cardiologists and endocrinologists are necessary when caring with patients with diabetes who have had cardiovascular issues in the past, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.
Collaboration between cardiologists and endocrinologists are necessary when caring with patients with diabetes who have had cardiovascular issues in the past, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.
Transcript
How can endocrinologists, cardiologists, and primary care providers collaborate to improve care for people with diabetes?
I think that this is the time to start thinking about collaboration between cardiologists and endocrinologists. We have some collaboration with primary care, because actually primary care is the first step where a patient is seen. The biggest problem is diabetes is changing too rapidly. We have new guidelines every year. We have new medications every year. We have new data on cardiovascular outcome trials. And according to the RAND Corporation, it takes many years for all the new information to get into the clinician.
I can tell you also that once a patient with diabetes has any cardiovascular issues, they see the cardiologist 5 more times than the endocrinologist. So, we need to keep the cardiologist updated on how to treat diabetes and what drugs are best for the patients if they already have previous cardiovascular events.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More